「Meningococcus」の版間の差分

提供: Vaccipedia | Resources for Vaccines, Tropical medicine and Travel medicine
ナビゲーションに移動 検索に移動
 
(同じ利用者による、間の3版が非表示)
73行目: 73行目:
  
 
===Interactions of MenACWY conjugate vaccines and other vaccines===
 
===Interactions of MenACWY conjugate vaccines and other vaccines===
 +
{|class="wikitable"
 +
|-
 +
!
 +
!MenACWY-DT
 +
*conjugated with diphtheria toxoid
 +
*メナクトラ Menactra
 +
!MenACWY-TT
 +
*conjugated with tetanus toxoid
 +
*メンクアッドフィ MenQuadfi
 +
|-
 +
!PCV7
 +
*conjugated with DT
 +
|
 +
*In a clinical trial of Menactra<sup>1)</sup>
 +
*Concomitant administration of Menactra+PCV7 at 12 months of age showed '''unmet non-inferiority criteria of pneumococcal IgG in 3 serotypes''' out of 7 in PCV7
 +
|
 +
|-
 +
!PCV13
 +
*conjugated with DT
 +
|
 +
|
 +
*MenQuadfi+PCV13 can be administered concomitantly<sup>2)</sup>, though SBA of serogroup A was lower of unknown clinical relevance
 +
|-
 +
!Td
 +
|
 +
*In an RCT<sup>1)</sup>
 +
*Serum bactericidal assay (SBA) titers of serogroups C, W and Y in 11-17 years of age were '''higher in concomitant administration of Menactra+Td''' than single Menactra
 +
|
 +
|-
 +
!DTaP
 +
*containing DT & TT
 +
|
 +
*In an RCT<sup>1)</sup>
 +
*SBA titers of all 4 serogroups in 4-6 years of age were '''lower in [DTaP (DAPTACEL) → 30days → Menactra]''' than in [Menactra → 30days → DTaP (DAPTACEL)]
 +
|
 +
|-
 +
!Tdap
 +
*containing DT & TT
 +
|
 +
|
 +
*MenQuadfi+Tdap can be administered concomitantly<sup>2)</sup>, though antibody titer against pertussis antigen PT was non-inferior whereas titers against pertussis FHA, RPN and FIM were lower of unknown clinical relevance
 +
|}
 +
 +
{{quote|content=
 +
*1) [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d8781ff-9366-462c-8161-6e958f44fcb4 14.3 Concomitant Vaccine Administration, Drug LabelInformation, MENACTRA. DailyMed, National Library of Medicine] (last accessed 15th Feb 2023)
 +
*2) [https://www.ema.europa.eu/documents/product-information/menquadfi-epar-product-information_en.pdf 4.5 Interaction with other medicinal products and other forms of interaction, MenQuadfi:EPAR-Product information, European Medicines Agency] (last accessed 15th Feb 2023)
 +
 +
}}

2023年2月15日 (水) 17:43時点における最新版

Navigation Menu Vac logo.png
General issues of Vaccine
Cold chain
Correlates of Protection
Vaccines for Asplenia
Vaccines for Pregnant women
Vaccines for Immunocompromised hosts
Vaccine hesitancy
Additional materials of vaccine
General issues of Tropical med.
Definition of Tropical Medicine
Matrices of tropical infection
General issues of Helminths
Neglected Tropical Diseases
Sexually-transmitted infections
Non-Communicable Diseases
Maternal health and contraception
Child health
Malnutrition and Micronutrient
Eosinophilia
Fever in the tropics
Diarrhea in the tropics
Anemia in the tropics
Dermatology in the tropics
Ophthalmology in the tropics
Neurology in the tropics
Mental health in the tropics
Surgery in the tropics
Humanitarian emergency
Epidemiology in outbreak
Antimicrobial resistance
Pathology of infectious diseases
General issues of Travel med.
Epidemiology of Travel health
Last minute traveler
Time zone issue
High altitude medicine
Diving medicine
Pregnancy and travel
Children and travel
Elderly and travel
Immunology
Principle of human immune system
Innate immunity
Cellular immunity
Humoral immunity
Neutralizing antibody and its assay
Antigenic Cartography
Additional materials of immunology
Epi & Stats
Basics & Definition
Epidemiology
Odds in statistics and Odds in a horse race
Collider bias
Data distribution
Statistical test
Regression model
Multivariate analysis
Marginal effects
Prediction and decision
Table-related commands in STATA
Missing data and imputation
Virus
HIV
HIV-TB co-infection
HIV-STI interaction
Viral Hemorrhagic Fever
Ebola
Crimean-Congo hemorrhagic fever
SFTS
Rabies
Polio
Dengue
Yellow fever
Chikungunya
Zika
Japanese encephalitis
Tick-borne encephalitis
Viral hepatitis
Measles
Smallpox and Monkeypox
Respiratory Syncytial virus
COVID-19
Bivalent BA.1/BA.4-5 mRNA vaccines
Monovalent XBB-1.5 mRNA vaccine
Private archives of the initial phase of the pandemic
Private archives of lecture materials of COVID vaccine as of March 2021
厚生労働省が発出する保健行政関連の文書の読み解き方
Bacteria
Bacteriological tests
Tuberculosis
Tuberculosis in Children
HIV-TB co-infection
Leprosy
Dermatological mycobacterium infecions
Syphilis and Yaws
Plague
Pneumococcus
Meningococcus
Typhoid
Salmonellosis
Melioidosis
Leptospirosis
Brucellosis
Bartonellosis
Lyme disease and Relapsing fever
Tularaemia
Tetanus
Diphtheria
Anthrax
Coxiellosis
Rickettsia
Rickettsiosis
Scrub typhus
Spotted fevers
Epidemic typhus
Murine typhus
Protozoa
Overview of protozoa
Overview of medicine for protozoa
Malaria
Chagas disease
African trypanosomiasis
Leishmaniasis
Trichomoniasis
Toxoplasmosis
Amoebiasis
Giardiasis
Cryptosporidiosis
Cyclosporiasis
Isosporiasis
Pentatrichomoniasis
Microsporidiasis
Babesiosis
Fungi
General issues of fungi
Coccidioidomycosis
Paracoccidioidomycosis
Histoplasmosis
Talaromycosis
Blastomycosis
Sporotrichosis
Nematode (roundworm)
Nematode principles
Lympatic filariasis
Onchocerciasis
Loiasis
Microscopic differentiation of microfilariae
Strongyloidiasis
Ascariasis
Ancylostomiasis (hookworm)
Trichuriasis (whipworm)
Enterobiasis (pinworm)
Angiostrongyliasis (rat lungworm)
Dracunculiasis (Guinea worm)
Anisakiasis
Trichinellosis (Trichinosis)
Gnathostomiasis
Spirurinasis
Soil-transmitted helminths
Trematode (fluke, distoma)
General issues of Helminths
Trematode principles
Schistosomiasis
Clonorchiasis
Fascioliasis
Paragonimiasis
Metagonimiasis
Cestode (tapeworm)
General issues of Helminths
Cestode principles
Diphyllobothriasis
Sparganosis
Taeniasis
Echinococcosis
Medical Zoology
Zoonosis
Insectology
Mosquitology
Acarology
Batology
Snake toxicology
Scorpion and spider toxicology
Marine toxicology

Chevron-up-blue.png

pathogen

  • Neisseria meningitidis
  • gram negative diplococci
  • carriage in nasopharynx
  • 12 identified capsular serogroups
  • common pathogenic serogroup A, B, C, W, X, Y
  • seasonal epidemics by group A, C
    • meningitis belt
  • sporadic cases by e.g. group B
    • Latin America
    • Norway
    • New Zealand
  • immunity generated by polysaccharide capsule except B
    • may be the reason that herd immunity development relatively slow and sporadic outbreaks continue in above countries

epidemiology

  • highest < 2 y/o and adolescent
  • annual outbreak during dry season in meningitis belt
    • dry winds make people's nose drier resulting in easier capture and membrane breakthrough
  • wide range difference of nasopharynx carriage between countries
    • reason totally unknown
    • NZ & 3%
    • Nigeria muslim boarding school 30-40%
  • 日本で戦後急速に発生が減ったのは,抗菌薬の導入普及と発熱早期での過剰投与,および住宅環境の改善による小児の集蔟が減少したためかもしれない

transmission

  • aerosol
  • fomite
  • adolescent activity

clinical picture

  • fever
  • distinctive petechiae anywhere in whole body
    • apparent pain accompanies with petechia in contrast to dengue
    • in earlier stage rashes are inflammation, not petechiae
  • no fading by pressure with glass tumbler - "tumbler test"
  • resulting in purple bruising of skin
  • photophobia
  • headache, neck stiffness, vomiting
  • irritability and/or confusion

vaccine

development history

  • 1960s - purified PS vaccines for A and C
    • immunity short term due to lack of T-cell involvement
  • 1990s - conjugated vaccines for A and C after success of Hib conjugate vaccine
  • 2000s - monovalent A vaccine for Africa
    • "MenAfriVac"

Development history of meningococcal vaccine.jpg

current vaccines

  • A polysaccharide
    • MenAfriVac
  • C conjugate
  • A,C,Y,W135 conjugate
    • Menactra (Sanofi Pasteur)
    • Menveo (GSK)
    • Nimenrix (Pfizer)
  • B protein (not polysaccharide)
    • Bexsero (GSK)
    • Trumenba (Pfizer)
    • VA-MENGOC-BC (Finlay Institute of Cuba)

issues of men B vaccine

  • polysaccharide of B is relatively low immunogenic
    • the reason is considered because of interaction between B polysaccharide and fetal brain tissue, resulting in possible immunotolerance
      • interaction is observed as antibodies against B-PS have also affinity to fetal brain tissue
    • it means B-PS vaccine has potential of neurological damage for young infants
  • currently available men B vaccines are protein-based vaccine, not PS vaccine
    • proteins expressed on the surface of N. meningitidis group B are purified through bacterial culture

Interactions of MenACWY conjugate vaccines and other vaccines

MenACWY-DT
  • conjugated with diphtheria toxoid
  • メナクトラ Menactra
MenACWY-TT
  • conjugated with tetanus toxoid
  • メンクアッドフィ MenQuadfi
PCV7
  • conjugated with DT
  • In a clinical trial of Menactra1)
  • Concomitant administration of Menactra+PCV7 at 12 months of age showed unmet non-inferiority criteria of pneumococcal IgG in 3 serotypes out of 7 in PCV7
PCV13
  • conjugated with DT
  • MenQuadfi+PCV13 can be administered concomitantly2), though SBA of serogroup A was lower of unknown clinical relevance
Td
  • In an RCT1)
  • Serum bactericidal assay (SBA) titers of serogroups C, W and Y in 11-17 years of age were higher in concomitant administration of Menactra+Td than single Menactra
DTaP
  • containing DT & TT
  • In an RCT1)
  • SBA titers of all 4 serogroups in 4-6 years of age were lower in [DTaP (DAPTACEL) → 30days → Menactra] than in [Menactra → 30days → DTaP (DAPTACEL)]
Tdap
  • containing DT & TT
  • MenQuadfi+Tdap can be administered concomitantly2), though antibody titer against pertussis antigen PT was non-inferior whereas titers against pertussis FHA, RPN and FIM were lower of unknown clinical relevance